Immunotherapy-related hepatitis: real-world experience from a tertiary centre
<p><strong>Objective</strong> Immune checkpoint inhibitors like anti-programmed cell death protein 1 (PD-1) drugs Nivolumab and Pembrolizumab and anti-cytotoxic T-lymphocyte associated (CTLA-4) drug Ipilimumab have become standard of care in many metastatic cancers. Immunotherapy-r...
Main Authors: | Cheung, V, Gupta, T, Payne, M, Middleton, MR, Collier, JD, Simmons, A, Klenerman, P, Brain, O, Cobbold, JF |
---|---|
Format: | Journal article |
Published: |
BMJ Publishing Group
2019
|
Similar Items
-
“Real world” experience in cardiac resynchronisation therapy at a Swiss tertiary care centre: update 2016
by: Stephan Winnik, et al.
Published: (2017-04-01) -
Fertility and reproduction in a tertiary IBD centre: the Oxford experience
by: Lee, L, et al.
Published: (2018) -
Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience
by: Yue (Jennifer) Du, et al.
Published: (2023-09-01) -
Development of novel treatments for hepatitis C.
by: Webster, D, et al.
Published: (2009) -
Seroprevalence of Hepatitis E Antibodies in Asymptomatic Antenatal Women from Tertiary Care Centre, Puducherry
by: Mohammed Riyaz, et al.
Published: (2023-06-01)